FDA approves groundbreaking Alzheimer’s drug Leqembi — here’s why patients still won’t have access
After months of anticipation, the U.S. Food and Drug Administration (FDA) has finally granted traditional approval to lecemab, a drug that’s been shown to significantly slow the progression of Alzheimer’s. Sold under the the brand name Leqembi, the medicine received an accelerated approval in January but the designation was made official on Thursday, per an … Read more